940 2016 11 1 41 11 [ ] (NFA) 1996 2 2016 1 NFA 243 (57 ) (186 ) NFA NFA ROC 57 27 30 31 25 1 4.5cm 18~71(41.5±12.1) 186 87 99 99 86 1 3.0cm 13~76(50.6±10.9) Logistic (OR=1.340 95%CI 1.266~1.418 P=0.000) (OR=0.942 95%CI 0.929~0.955 P=0.000) ROC (AUC) 0.757(95%CI 0.681~0.833) 4.1cm NFA Youden ( 60.7% 83.0%) NFA 4.1cm NFA [ ] [ ] R736.6 [ ] A [ ] 0577-7402(2016)11-0940-05 [DOI] 10.11855/j.issn.0577-7402.2016.11.11 suitable for surgery LIU Dan-dan, LI Le-le, DOU Jing-tao *, HAN Bai-yu, ZANG Li, JIN Nan, GU Wei-jun, DU Jin, YANG Li-juan, BA Jianming, LV Zhao-hui, LU Ju-ming, MU Yi-ming Department of Endocrinology, Key Laboratory of Endocrinology and Metabolism of PLA, Chinese PLA General Hospital, Beijing 100853, China * Corresponding author, Email: jingtaodou@ sohu.com [Abstract] Objective To analyze the pathology of the patients with nonfunctional adrenal tumor (NFA), and explore the optimal diameter cut-off value. Methods The clinical data of 243 patients with NFA, evaluated in the Department of Endocrinology and operated in the Department of Urology of General Hospital of Chinese PLA from Feb. 1996 to Jan. 2016, were collected. The patients were divided into two groups according to pathology: those in real demand of surgery were classified to the surgery-need group (n=57), while the others were categorized as the surgery-unwanted group (n=186). The general situation, pathological type and tumor diameter of the two groups and the factors affecting the surgery were analyzed, and the ROC curve was used to explore the optimal surgery cut-off value, which represents the maximum value of the sum of sensitivity and specificity. Results Of the 57 patients in surgery-need group (27 males and 30 females), the lesions were on the right in 31 cases, on the left in 25 cases, and on bilateral sides in 1 case; the median of lesion diameter was 4.5cm, and the average age was 41.5±12.1 years old. Of the 186 patients in surgery-unwanted group (87 males and 99 females), the lesions were on the right in 99 cases, on the left in 86 cases, and on bilateral sides in 1 case; the median of lesion diameter was 3.0cm, and the average age was 50.6±10.9 years old. Logistic regression revealed that lesion diameter might be a risk factor (OR=1.340, 95%CI 1.266-1.418, P=0.000) and age be a protective factor (OR=0.942, 95%CI 0.929-0.955, P=0.000) for real demand of surgery. The area under the ROC curve (AUC) of lesion diameter was 0.757(95%CI 0.681-0.833). The optimal cut-off value was 4.1cm (sensitivity 60.7% and specificity 83.0%). Conclusions Younger patients with bigger lesion diameter may have greater possibility for surgery. The optimal surgery cut-off value of the lesion diameter is 4.1cm. [Key words] adrenocortical adenoma; endocrine surgical procedures; lesion diameter [ ] [ ] 100853 ( ) [ ] E-mail jingtaodou@sohu.com
Med J Chin PLA, Vol. 41, No. 11, November 1, 2016 941 (nonfunctional adrenal tumor NFA) 49.9% [1] NFA 2009 (AACE) (AAES) [2] CT 4cm NFA 80% NFA NFA NFA 1 1.1 1996 2 2016 1 243 NFA NFA 1.2 1.2.1 243 [3-14] [15-19] 57 61 1 4 1 2 186 194 1 2 1 3 2 2 2 2 1 2 1.2.2 - (ACTH-F) 1mg (1mg DST) <50nmol/L 24h (24h UFC) 2 24h (NE) (E) (DA) / 4 2 24 (pmol/l)/ [ g/(l.h)] (ARR)<30 CT CT 10Hu 20~40Hu CT 80~90Hu 10~15min 50% [2] 1.2.3 [20] 1.3 SPSS 17.0 x±s t ( Q) (%) χ 2 Logistic ROC P<0.05 2 2.1 57 27 (47.4%) 30 (52.6%) 31 (54.4%) 25 (43.9%) 1 (1.8%) 18~71(41.5±12.1) 186 87 (46.8%) 99 (53.2%) 99 (53.2%) 86 (46.2%) 1 (0.5%) 13~76(50.6±10.9) (P<0.05) ( 1) 2.2 2 61 194 1 4.5(Q=3.25)cm
942 2016 11 1 41 11 1 Tab.1 Comparison of general conditions between two groups Item Surgery-need group (n=57) Surgery-unwanted group (n=186) t-value/χ 2 -value P-value Gender (Male/Female) 27/30 87/99 0.008 0.928 Lesion location (Right/Left/Bilateral) 31/25/1 99/86/1 2.106 0.349 Visiting ages (x±s, year) 41.5±12.1 50.6±10.9 5.340 0.000 2 243 Tab.2 Distribution of pathological pattern and grouping status of 243 patients with NFA Surgery-need group Case Excised lesion number Surgery-unwanted group Case Excised lesion number Total number 57 61 Total number 186 194 Malignant lymphoma 2 5 Adenoma sebaceum (one case accompanied by cystic change) 142 147 Liposarcoma 1 1 Myelolipoma 19 21 Cortical carcinoma 1 1 Hydatoncus (one case is epidermoid cyst) 13 13 Pheochromocytoma 18 18 Adrenal hyperplasia 5 6 Ganglioneuroma 18 19 Hematoma 3 3 Neurinoma 4 4 Hematolymphangioma (one case accompanied by partial calcification) 2 2 Neurofibroma 2 2 Lymphangioma 2 2 Adenoma tumor (One case accompanied a large number of necrosis) 3 3 Cavernous hemangioma (One case accompanied hematoma) 3 3 Perivascular epithelioid cell tumor 2 2 Angiomyolipoma 1 1 Mature cystic teratomas 1 1 Adrenal hyperplasia with bleeding 1 1 3.0(Q=1.85)cm (Mann-Whitney U=2879.000 Z= 0.068 P=0.000) 20.0 Lesion diameter (cm) 15.0 10.0 5.0 4.1cm 0.0 Surgery-need group Surgery-unwanted group 1 Fig.1 Comparison of contribution of the lesion diameters between two groups 2.3 NFA Logistic NFA (OR=1.340 95%CI 1.266~1.418 Wals =102.342 P=0.000) (OR=0.942 95%CI 0.929~0.955 Wals = 76.669 P=0.000) NFA ( =1.667 P=0.197) ( =0.316 P=0.574) 2.4 ROC ( 2) ROC (AUC) 0.757(95%CI 0.681~0.833) (0.5) 4.1cm Sensitivity 1.0 0.8 0.6 0.4 0.2 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1-Specificity 2 ROC Fig.2 ROC curve taking postoperative pathology as diagnosis index
Med J Chin PLA, Vol. 41, No. 11, November 1, 2016 943 Youden ( 1 60.7% 83.0%) 43.7% 3 4cm 68.9% 70.6% Youden 39.5% 3 Youden (%) Tab.3 Sensitivity, specificity and Youden index of NFA with different surgery cut-off value (%) Surgery cut-off value (cm) Sensitivity Specificity Youden index 2.0 90.2 14.4 4.6 2.5 88.5 26.8 15.3 3.0 88.5 41.2 29.7 3.5 77.0 59.3 36.3 4.0 68.9 70.6 39.5 4.1 60.7 83.0 43.7 4.5 57.4 84.0 41.4 5.0 41.0 90.0 31.0 5.5 36.1 94.3 30.4 6.0 29.5 94.8 24.3 3 NFA [21] 19 3 [3-8] [9] [10-11] [12-13] [14] [15-16] [17-18] [19] ROC 4.1cm 2000 Mantero [22] 1004 >4cm 73% >4cm ROC 4cm 2009 AACE/AAES 4cm [2] 2012 Wang [23] CT MRI <4cm ( ) <65 >4cm 4cm 4.1cm Youden 39.5% 4.1cm Youden (43.7%) Cho [24] 243 NFA 22.5 4.2% AACE/AAES 3~6 1~2 5 1cm [2] NFA 4.1cm
944 2016 11 1 41 11 [1] Li LL, Dou JT, Gu WJ, et al. Clinical analysis of 4 049 hospitalized cases of adrenal lesions[ J]. Chin Med J, 2014, 94(42): 3314-3318. [,,,. 4049 [J]., 2014, 94(42): 3314-3318.] [2] Zeiger MA, Thompson GB, Duh QY, et al. American association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations[ J]. Endocr Pract, 2009, 15(Suppl 1): 1-20. [3] Jung HR, Kang KJ, Kwon JH, et al. Adrenal ganglioneuroma with hepatic metastasis[ J]. J Korean Surg Soc, 2011, 80(4): 297-300. [4] Jia XP, Sun YN, Li WP, et al. Diagnosis and therapy of adrenal ganglioneuromas[ J]. Chin J Urol, 2012, 33(4): 247-249. [,,. [J]., 2012, 33(4): 247-249.] [5] Zeng ZP. Neuroblastoma and some other related tumors[m]. //Chen JL. Clinical endocrinology. Shanghai: Science and Technology of China Press, 2011. 644-646. [. [M]. //.. :, 2011. 644-646.] [6] Zhao L, Tu XA, Qiu SP, et al. Adrenal neurofibroma[ J]. J Clin Urol, 2007, 22(3): 184. [,,,. 1 [J]., 2007, 22(3): 184.] [7] Pant L, Kalita D, Chopra R, et al. Malignant perivascular epithelioid cell tumor (pecoma) of the adrenal gland: report of a rare case posing diagnostic challenge with the role of immunohistochemistry in the diagnosis[ J]. Endocr Pathol, 2015, 26(2): 1-6. [8] Huang DF, Wang YY. Left cystic mature adrenal teratoma: a case report[ J]. J South Med Univ, 2013, 33(1): 159-161. [,. 1 [J]., 2013, 33(1): 159-161.] [9] Li M, Wu B, Song YS, et al. Clinical analysis of adrenal schwannoma[ J]. J Mod Oncol, 2014, 22(11): 2666-2668. [,,,. [J]., 2014, 22(11): 2666-2668.] [10] Wojewoda CM, Wasman JK, Maclennan GT. Adenomatoid tumor of the adrenal gland[ J]. J Urol, 2008, 180(3): 1123. [11] Huang YJ, Yu WY. The observation of clinicopathologic feature in patients with adrenal adenoma tumor[ J]. Mod Practical Med, 2014, 26(2): 178-179. [,. [J]., 2014, 26(2): 178-179.] [12] Cheng P, Wu P, Gang Z. A rare cavernous hemangioma of the adrenal gland[ J]. Urol Case Rep, 2015, 4(4): 106-108. [13] Tyritzis SI, Adamakis I, Migdalis V, et al. Giant adrenal myelolipoma, a rare urological issue with increasing incidence: a case report[ J]. Cases J, 2009, 2: 8863. [14] Toniato A, Boschin I, Opocher G, et al. Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment?[ J]. Surgery, 2007, 141(6): 723-727. [15] Qu LX, Li LP, Wang X, et al. Diagnosis and treatment of adrenal myelolipoma[ J]. Fudan Univ J Med Sci, 2012, 39(3): 297-300. [,,,. [J]. :, 2012, 39(3): 297-300.] [16] Nasir A, Hubbard JG, Moonim MT. Adrenal lymphangioma presenting as a non-functional adrenal cyst[ J]. Gland Surg, 2015, 4(6): 561-563. [17] Major P, P dziwiatr M, Mat ok M, et al. Cystic adrenal lesions - analysis of indications and results of treatment[ J]. Pol Przeql Chir, 2012, 84(4): 184-189. [18] Wang D, Li HZ, Shi BB, et al. Clinical analysis of 155 adrenal cyst cases[ J]. Basic Clin Med, 2012, 32(1): 7-11. [,,. 155 [J]., 2012, 32(1): 7-11.] [19] Sasaki K, Yamada T, Gotoh K, et al. Idiopathic adrenal hematoma masquerading as neoplasm[ J]. Case Rep Gastroenterol, 2012, 6(1): 171-176. [20] Fu B, Zhang X, Wang GX, et al. Retroperitoneoscopy surgery methods and skills of adrenal large tumors.[ J]. J Minim Invasive Urol, 2013, 2(5): 289-292. [,,,. [J]., 2013, 2(5): 289-292.] [21] Liu Y, Hu RM. Diagnosis and treatment for adrenal diseases in the elderly[ J]. Chin J Pract Intern Med, 2011, 31(11): 841-843. [,. [J]., 2011, 31(11): 841-843.] [22] Mantero F, Terzolo M, Arnaldi G, et al. Asurveyonadrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology[ J]. J Clin Endocrinol Metab, 2000, 85(2): 637-644. [23] Wang TS, Cheung K, Roman SA, et al. A cost-effectiveness analysis of adrenalectomy for nonfunctional adrenal incidentalomas: is there a size threshold for resection?[ J]. Surgery, 2012, 152(6): 1125-1132. [24] Cho YY, Suh S, Joung JY, et al. Clinical characteristics and followup of Korean patients with adrenal incidentalomas[ J]. Korean J Intern Med, 2013, 28(5): 557-564. ( 2016-07-12 2016-09-17) ( )